Feasibility of such an approach was demonstrated in melanoma, where myriocin treatment induced growth arrest in vitro [49] and suppressed tumor growth in a murine melanoma model via p53- and p21-dependent pathways [50] as observed during the present study (Fig. 3C–E). The gene discussed is TP53; the disease is melanoma.